Cannabis Stocks Watchlist: Canopy Growth Falls After Closures

Daily Updates


The MORE Act was passed this past week and it was the first time that any cannabis bill addressing descheduling was approved by Congress. This bill will also change the tax code and allow companies to deduct certain expenses.

For more in-depth coverage of the cannabis sector including buy and sell recommendations and investment strategies, follow Debra Borchardt on Real Money.

Here is a list of the cannabis stocks to watch and their performance from this past week by the percentage change at the close of trading on Dec. 11.

Aurora Cannabis Inc | Decreased -9.09% | Price $9.91

Aurora Cannabis  (ACB) – Get Report was the cannabis stock to keep an eye on this past week and it disappointed. Aurora is now down 59 percentage points year to date. 

TheStreet Quant Ratings rates Aurora Cannabis Inc. as a Sell with a rating score of D-.

Arena Pharmaceuticals | Increased +3.19% | Price $69.91

Arena Pharmaceuticals  (ARNA) – Get Report was one of the few stocks this week to rise. Arena Pharmaceuticals has a diversified list of drugs covering several illnesses. 

TheStreet Quant Ratings rates Arena Pharmaceuticals as a Hold with a rating score of C.

Cronos Group Inc | Decreased -7.53% | Price $7.98

Cronos Group  (CRON) – Get Report is up over eight percentage points year to date but fell this past week. Cronos Group will try to rise again this upcoming week. 

TheStreet Quant Ratings rates Cronos Group as a Sell with a rating score of D.

Tilray Inc | Decreased -9.65% | Price $7.77

Tilray  (TLRY) – Get Report is down over 50 percentage points year to date and fell again this past week. Investors are asking themselves if now is the time to buy the bottom with Tilray.

TheStreet Quant Ratings rates Tilray as a Sell with a rating score of D.

Cara Therapeutics | Decreased -1.13% | Price $14.91

Cara Therapeutics  (CARA) – Get Report shares were mixed this week but the lead independent director recently sold shares.

TheStreet Quant Ratings rates Cara Therapeutics as a Sell with a rating score of D.

Canopy Growth Corp | Decreased -7.21% | Price $26.53

Canopy Growth  (CGC) – Get Report is reducing its operations which helped the stock early in the week but unfortunately, shares fell at the end of the week.

TheStreet Quant Ratings rates Canopy Growth Corp as a Hold with a rating score of C.

GW Pharmaceuticals | Decreased -12.41% | Price $120.43

GW Pharmaceuticals  (GWPH) – Get Report is one of the most popular cannabis companies to buy. After shares fell over 12 percentage points, could this be the time to buy?

TheStreet Quant Ratings rates GW Pharma as a Sell with a rating score of D+.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *